(NASDAQ: LXEO) Lexeo Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.65%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.44%.
Lexeo Therapeutics's earnings in 2026 is -$87,265,000.On average, 12 Wall Street analysts forecast LXEO's earnings for 2026 to be -$101,819,402, with the lowest LXEO earnings forecast at -$104,526,929, and the highest LXEO earnings forecast at -$100,793,824. On average, 11 Wall Street analysts forecast LXEO's earnings for 2027 to be -$114,183,773, with the lowest LXEO earnings forecast at -$139,905,274, and the highest LXEO earnings forecast at -$99,070,853.
In 2028, LXEO is forecast to generate -$100,785,620 in earnings, with the lowest earnings forecast at -$157,594,447 and the highest earnings forecast at -$62,026,969.